Login / Signup

A long-term, open-label study of valbenazine for tardive dyskinesia.

Jean-Pierre LindenmayerCherian VergheseStephen R MarderJoshua BurkeRoland JimenezScott SiegertGrace S LiangChristopher F O'Brien
Published in: CNS spectrums (2020)
Valbenazine was well-tolerated and persistent improvements in TD were found in adults who received once-daily treatment for >1 year.
Keyphrases
  • open label
  • clinical trial
  • physical activity
  • randomized controlled trial
  • squamous cell carcinoma
  • combination therapy
  • radiation therapy
  • phase iii
  • rectal cancer
  • replacement therapy